[1]王红艳,潘 利.自拟抑癌汤联合阿帕替尼治疗对中晚期胃癌患者的疗效及对血清CEA、CA199的影响[J].医学信息,2021,34(14):166-168.[doi:10.3969/j.issn.1006-1959.2021.14.047]
　WANG Hong-yan,PAN Li.Efficacy of Self-made Anti Cancer Soup Combined with Apatinib on Patients with Middle and Advanced Gastric Cancer and Its Effect on Serum CEA,CA199[J].Medical Information,2021,34(14):166-168.[doi:10.3969/j.issn.1006-1959.2021.14.047]
点击复制

自拟抑癌汤联合阿帕替尼治疗对中晚期胃癌患者的疗效及对血清CEA、CA199的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年14期
页码:
166-168
栏目:
中医中药
出版日期:
2021-07-15

文章信息/Info

Title:
Efficacy of Self-made Anti Cancer Soup Combined with Apatinib on Patients with Middle and Advanced Gastric Cancer and Its Effect on Serum CEA,CA199
文章编号:
1006-1959（2021）14-0166-03
作者:
王红艳; 潘 利
（北大医疗海洋石油医院中医科1，外科2，天津 300452）
Author(s):
WANG Hong-yan; PAN Li
(Department of Traditional Chinese Medicine1,Department of Surgery2,Peking University Medical Offshore Oil Hospital, Tianjin 300452,China)
关键词:
胃癌; 阿帕替尼; 自拟抑癌汤; 毒副反应
Keywords:
Gastric cancer; Apatinib; Self-made anticancer soup; Side effects
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2021.14.047
文献标志码:
A
摘要:
目的 探讨自拟抑癌汤联合阿帕替尼治疗对中晚期胃癌患者的疗效及对血清CEA、CA199的影响。方法 选取2016年7月~2018年8月我院接受治疗的中晚期胃癌患者46例，根据治疗方式不同分为西药组和联合组，每组23例。西药组给予阿帕替尼治疗，联合组给予自拟抑癌汤联合阿帕替尼治疗，比较两组临床疗效、治疗前后血清CEA、CA199水平及毒副反应发生情况。结果 联合组肿瘤控制率为91.30%、治疗有效率为78.26%，高于西药组的73.91%、56.52%，差异有统计学意义（P＜0.05）；联合组血清CEA、CA199水平低于西药组，差异有统计学意义（P＜0.05）；联合组毒副反应总发生率为13.04%，低于西药组的34.78%，差异有统计学意义（P＜0.05）。结论 自拟抑癌汤联合阿帕替尼治疗中晚期胃癌患者疗效理想，可降低血清CEA、CA199水平，且毒副反应发生率低，用药安全性高。
Abstract:
Objective To investigate the effect of self-madeanticancer soupcombined with apatinib on patients with advanced gastric cancer and its effect on serum CEA and CA199.Methods A total of 46 patients with advanced gastric cancer who were treated in our hospital from July 2016 to August 2018 were selected and divided into western medicine group and combination group according to different treatment methods, with 23 cases in each group.The western medicine group was treated with apatinib, and the combination group was treated with self-madeanticancer soup combined with apatinib. The clinical efficacy and serum CEA and CA199 levels and the occurrence of toxic and side effects before and after treatment were compared between the two groups.Results The tumor control rate of the combined group was 91.30%, and the effective rate of treatment was 78.26%, which was higher than 73.91% and 56.52% of the western medicine group,the difference was statistically significant(P<0.05);The serum CEA and CA199 levels in the combination group were lower than those in the western medicine group,the difference was statistically significant (P＜0.05); The total incidence of side effects in the combined group was 13.04%, which was lower than 34.78% in the western medicine group,the difference was statistically significant(P<0.05).Conclusion The self-madeanticancer soupcombined with apatinib has an ideal effect in the treatment of patients with advanced gastric cancer. It can reduce serum CEA and CA199 levels, and has a low incidence of toxicity and high drug safety.

参考文献/References:

[1]李恒,王莎莎.益气健脾活血汤防治晚期胃癌经贝伐珠单抗靶向治疗所致尿白蛋白、高血压的疗效及对Th1/Th2免疫漂移及肿瘤标记物的影响[J].现代中西医结合杂志,2020,29(30):3331-3335. [2]房玮,吴红卫,李莹莹.中药联合化疗治疗胃癌的临床效果分析[J].实用癌症杂志,2015,30(11):1668-1671. [3]李德錄,郑莹,李敏,等.上海市推行《中国常见恶性肿瘤诊治规范》(胃癌)的效果评估[J].外科理论与实践,2004(2):130-132. [4]鲍瑜,钱江,宋文灿,等.阿帕替尼联合替吉奥一线治疗晚期胃癌临床研究[J].中国药业,2019,28(11):74-77. [5]张玥,梁聪.阿帕替尼治疗标准化疗失败晚期胃癌患者的疗效及对血清癌胚抗原和糖类抗原199水平的影响[J].中国肿瘤临床与康复,2020,27(5):521-524. [6]Huang SF,Chien TH,Fang WL,et al.The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of locally advanced disease[J].Eur J Surg Oncol,2018,44(10):1634-1639. [7]黄毅超,刘云军,何宛谦,等.阿帕替尼与替吉奥联合治疗晚期胃癌疗效分析及对相关细胞因子的影响[J].中国中西医结合消化杂志,2018,26(3):252-255. [8]徐薇.健脾解毒方辅助化疗治疗晚期胃癌的疗效及安全性观察[J].光明中医,2019,34(5):767-769. [9]朱冬菊.阿帕替尼联合中药治疗晚期恶性肿瘤的疗效和不良反应的回顾性研究[D].北京中医药大学,2019. [10]沙晓锋,张姣.安替可胶囊联合FOLFOX6方案对晚期胃癌患者血管生长因子、肿瘤标志物、生活质量的影响[J].现代中西医结合杂志,2020,29(15):1672-1675. [11]王燚霈,李擎虎,彭瑶,等.菊藻丸联合化疗对中晚期胃癌患者临床效果及生活质量的影响[J].世界中西医结合杂志,2019,14(5):700-703,711. [12]窦建卫,杨小娟,李康乐,等.从气机升降探讨胃癌的病机治则[J].辽宁中医杂志,2020,47(2):82-83. [13]宋丽,高湘湘,张珣磊,等.血清CEA、CA199作为晚期胃癌疗效评价指标的临床价值[J].南通大学学报(医学版),2016,36(6):623-624,625. [14]王荦楠,姬颖华,靳彩玲.阿帕替尼联合DCF化疗方案治疗晚期胃癌临床疗效及对肿瘤标志物水平的影响[J].西藏医药,2018,39,139(4):16-19. [15]吕伯乐.阿帕替尼联合替吉奥治疗晚期胃癌患者的疗效及对其血清肿瘤标志物,Th1/Th2细胞因子水平的影响[J].中国民康医学,2020,32(11):3-4,7.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
　YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,31(14):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,31(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
　RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Medical Information,2018,31(14):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
　DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Medical Information,2018,31(14):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,31(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
　PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Medical Information,2018,31(14):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]李虹霞,刘伏山.慢性萎缩性胃炎的中西医治疗[J].医学信息,2022,35(11):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
　LI Hong-Xia,LIU Fu-shan.Treatment of Chronic Atrophic Gastritis with Traditional Chinese and Western Medicine[J].Medical Information,2022,35(14):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
[6]李 光.替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析[J].医学信息,2018,31(16):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
　LI Guang.Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer[J].Medical Information,2018,31(14):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
[7]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(14):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[8]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,31(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
　LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Medical Information,2018,31(14):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[9]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,31(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
　MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Medical Information,2018,31(14):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[10]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
　ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Medical Information,2018,31(14):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]

更新日期/Last Update: 1900-01-01